Beijing North Star (601588.SH) controlling shareholder's shareholding plan extended for 6 months.
Beichen Industrial (601588.SH) announced that on January 9, 2025, the company received a notice from its controlling shareholder Beichen Group...
Beijing North Star (601588.SH) issued an announcement on January 9, 2025, stating that the company received a letter from its controlling shareholder, Beichen Group, informing them that due to factors such as the window period for regular reports, information sensitivity period, and changes in the capital market situation, the planned increase in shareholding could not be completed within the original timeframe.
Based on their confidence in the company's future sustainable and steady development, as well as the recognition of its long-term investment value, Beichen Group intends to continue implementing the shareholding plan using its own funds and specialized loans from financial institutions. The deadline for the shareholding plan will be extended by 6 months to July 8, 2025, while the other contents of the plan remain unchanged.
This decision is made in response to investor concerns, to fulfill commitments, better protect the interests of investors, and strengthen investor confidence.
Related Articles

New stock first day | Kingway Pharmaceuticals-B (02595) debuted on the market with an opening increase of 115.79% in the morning session. Its core product GFH925 has already been commercialized domestically.

China Galaxy Securities: New Intelligent and Global Opportunities Enabled by New Quality Productivity. Suggestions focus on four main themes.

Guotai Junan International: Maintains "Buy" rating on BEAUTYFARM MED (02373) with a target price of 45 Hong Kong dollars.
New stock first day | Kingway Pharmaceuticals-B (02595) debuted on the market with an opening increase of 115.79% in the morning session. Its core product GFH925 has already been commercialized domestically.

China Galaxy Securities: New Intelligent and Global Opportunities Enabled by New Quality Productivity. Suggestions focus on four main themes.

Guotai Junan International: Maintains "Buy" rating on BEAUTYFARM MED (02373) with a target price of 45 Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025